MedTrace Logo

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

NCT05428930 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-11-17

No results posted yet for this study

Summary

A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501B in Glabellar lines.

Conditions

  • Glabellar Lines

Interventions

DRUG

CKDB-501B

Intramuscular injection CKDB-501B

DRUG

Botox®50U

Intramuscular injection Botox®50U

Sponsors & Collaborators

  • CKD Bio Corporation

    lead INDUSTRY

Principal Investigators

  • beomjoon Kim · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2022-10-25
Completion
2022-10-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05428930 on ClinicalTrials.gov